Chronic Lymphocytic Leukemia Update, Issue 1, 2019

Interview with William G Wierda, MD, PhD

Track 1: Evolution of the treatment paradigm for patients with chronic lymphocytic leukemia (CLL)
Track 2: Biomarker assessment for patients with newly diagnosed CLL
Track 3: Therapeutic approach for older patients with CLL; IGHV mutation status in treatment decision-making
Track 4: Case: A woman in her early 70s with CLL with deletion 17p, a p53 mutation and no IGHV mutation achieves a complete remission with ibrutinib and venetoclax as first-line therapy on a clinical trial
Track 5: Implications of del(17p) and p53 mutations in CLL pathogenesis and for the selection of treatment
Track 6: Efficacy of venetoclax alone and in combination with obinutuzumab or rituximab
Track 7: Phase II trial of ibrutinib with venetoclax for CLL
Track 8: Ongoing Phase II CAPTIVATE trial of ibrutinib with venetoclax as front-line therapy
Track 9: Relevance of minimal residual disease (MRD) as a clinical endpoint in CLL
Track 10: Effect of MRD status on outcomes in the Phase III MURANO trial evaluating venetoclax with rituximab for relapsed/refractory CLL
Track 11: Risk of tumor lysis syndrome (TLS) with venetoclax
Track 12: Prophylactic approaches for TLS associated with venetoclax
Track 13: Ongoing Phase III trial of ibrutinib and venetoclax; evaluation of ibrutinib/venetoclax in combination with an anti-CD20 antibody
Track 14: Potential clinical role of ibrutinib/venetoclax for patients with CLL
Track 15: Case: A man in his late 50s with idiopathic thrombocytopenic purpura and del(11q) CLL with no IGHV mutation receives acalabrutinib after multiple lines of therapy, including venetoclax and ibrutinib
Track 16: Efficacy and side-effect profile of acalabrutinib versus ibrutinib
Track 17: Results of the Phase III ASCEND study of acalabrutinib alone versus investigator’s choice of idelalisib/rituximab or bendamustine/rituximab for relapsed/refractory CLL
Track 18: Ongoing Phase III ELEVATE-TN trial of acalabrutinib alone versus acalabrutinib/obinutuzumab versus chlorambucil/obinutuzumab for previously untreated CLL
Track 19: Emerging data with next-generation, reversible Bruton tyrosine kinase inhibitors for CLL
Track 20: Mechanism of action, efficacy and tolerability of the recently FDA-approved antibody-drug conjugate moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia
Track 21: Case: A woman in her early 60s with del(17p) CLL and no IGHV mutation receives venetoclax and obinutuzumab as first-line therapy
Track 22: Activity and safety profile of chimeric antigen receptor (CAR) T-cell therapy for CLL
Track 23: Challenges in the clinical management of CLL

Interview with Anthony R Mato, MD, MSCE

Track 1: Emerging data and recent advances in the management of CLL
Track 2: Perspective on the role of MRD assessment in therapeutic decision-making
Track 3: Duration of therapy for patients with CLL; integration of venetoclax into the treatment algorithm
Track 4: Available data with the addition of rituximab or obinutuzumab to novel therapies
Track 5: Selection of patients with CLL for treatment with FCR (fludarabine/cyclophosphamide/rituximab)
Track 6: Novel combination approaches to limiting the duration of therapy for patients with CLL
Track 7: Spectrum and incidence of toxicities with ibrutinib/venetoclax compared to either agent alone
Track 8: Therapeutic options for patients with CLL in the first-line setting
Track 9: Safety profile and quality of life with venetoclax versus ibrutinib
Track 10: Frequency of and reasons for discontinuation of therapy with ibrutinib
Track 11: Left atrial abnormality as a predictor of ibrutinib-associated atrial fibrillation in patients with CLL
Track 12: Real-world outcomes and management strategies for patients with venetoclax-treated CLL in the United States
Track 13: Experience conducting real-world outcome studies
Track 14: Role of chemoimmunotherapy in the management of relapsed/refractory CLL
Track 15: Clinical experience with and management of ibrutinib-associated adverse events
Track 16: Investigation of ibrutinib in combination with CAR T-cell therapy for CLL
Track 17: Case: A woman in her mid-70s with del(17p) CLL and no IGHV mutation experiences arthralgia and hypertension during second-line therapy with ibrutinib
Track 18: Incidence and management of hypertension associated with ibrutinib
Track 19: Dose reductions of ibrutinib to mitigate side effects; effect on efficacy
Track 20: Case: A man in his mid-60s with a history of hypertension and atrial fibrillation receives acalabrutinib as first-line therapy for CLL
Track 21: Headaches and hypertension associated with acalabrutinib
Track 22: Comparative efficacy and spectrum of kinase activity with ibrutinib, acalabrutinib and zanubrutinib
Track 23: Activity and tolerability of acalabrutinib versus ibrutinib
Track 24: Case: A woman in her mid-50s with von Willebrand disease and CLL receives venetoclax after experiencing disease progression through several lines of therapy
Track 25: Dose adjustments of venetoclax and management of TLS
Track 26: Case: A woman in her late 80s with del(13q) CLL with IGHV mutation, symptomatic anemia and lymphadenopathy receives first-line obinutuzumab
Track 27: Clinical experience with obinutuzumab-associated infusion-related reactions
Track 28: Choice of first-line therapy for older patients with CLL
William G Wierda, MD, PhD
DB Lane Cancer Research Distinguished Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Anthony R Mato, MD, MSCE
Associate Attending
Director, Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, New York
Neil Love, MD
Research To Practice
Miami, Florida